Photo by lauramayela99 from unsplash
The poor survival of engrafted stem cells in the ischemic environment limits their therapeutic efficacy for myocardial infarction (MI) treatment. Previously, we demonstrated that GW4064, an farnesoid X receptor (FXR)… Click to show full abstract
The poor survival of engrafted stem cells in the ischemic environment limits their therapeutic efficacy for myocardial infarction (MI) treatment. Previously, we demonstrated that GW4064, an farnesoid X receptor (FXR) agonist, ameliorated post-MI cardiac dysfunction and remodeling. The current study
Keywords:
survival engrafted;
stem cells;
farnesoid receptor
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!